Publications

Detailed Information

Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: A multicenter study

DC Field Value Language
dc.contributor.authorLee, Won Ki-
dc.contributor.authorByun, Seok-Soo-
dc.contributor.authorKim, Hyeon Hoe-
dc.contributor.authorRha, Koon Ho-
dc.contributor.authorSung, Gyung Tak-
dc.contributor.authorLim, Jae Sung-
dc.contributor.authorKwon, Tae Gyun-
dc.contributor.authorJeong, Young Beom-
dc.contributor.authorLee, Wan-
dc.contributor.authorHwang, Tae-Kon-
dc.date.accessioned2012-06-14T06:15:20Z-
dc.date.available2012-06-14T06:15:20Z-
dc.date.issued2010-11-
dc.identifier.citationINTERNATIONAL JOURNAL OF UROLOGY; Vol.17 11; 898-904ko_KR
dc.identifier.issn0919-8172-
dc.identifier.urihttps://hdl.handle.net/10371/77070-
dc.description.abstractObjectives: To analyze the characteristics and the prognostic significance of chromophobe renal cell carcinomas (chRCC). Methods: Data about 2981 patients with non-metastatic renal cell carcinomas (RCC) at the time of surgery were retrospectively collected from 26 institutions between 1998 and 2008. All patients had undergone partial or radical nephrectomies. Of the 2981 patients, 2602 patients with conventional RCC (cRCC) and 148 with chRCC were studied. Clinical and pathological parameters were determined in all patients. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were assessed. Results: Patients with chRCC differed significantly from those with cRCC on the following parameters: younger age (P = 0.026), greater female ratio (P < 0.001), and larger tumor diameter (P < 0.001). Both groups were alike with respect to body mass index (P = 0.943), Eastern Cooperative Oncology Group performance status (P = 0.163), T stage (P = 0.375), and Fuhrman`s grade (P = 0.134). The 5-year RFS rates in patients with chRCC and cRCC were 82.7% and 83.3%, respectively (P = 0.762). The 5-year CSS rates in patients with chRCC and cRCC were 88.8% and 92.2%, respectively (P = 0.980). Both groups showed equivalent oncological outcomes in terms of RFS and CSS for cases stratified by T stage and Fuhrman`s grade. In multivariate analysis, the histological subtype was not retained as an independent prognostic variable (RFS: P = 0.893; CSS: P = 0.729). Conclusions: Despite being significantly different from cRCC in terms of several clinical and pathological parameters, chRCC shows equivalent oncological outcomes.ko_KR
dc.language.isoenko_KR
dc.publisherWILEY-BLACKWELLko_KR
dc.subjectchromophobeko_KR
dc.subjectsurvivalko_KR
dc.subjectrenal cell carcinomako_KR
dc.subjectpathologyko_KR
dc.subjectconventionalko_KR
dc.titleCharacteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: A multicenter studyko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이원기-
dc.contributor.AlternativeAuthor변석수-
dc.contributor.AlternativeAuthor김현회-
dc.contributor.AlternativeAuthor라군호-
dc.contributor.AlternativeAuthor황태곤-
dc.contributor.AlternativeAuthor성경탁-
dc.contributor.AlternativeAuthor이완-
dc.contributor.AlternativeAuthor임재성-
dc.contributor.AlternativeAuthor정용범-
dc.contributor.AlternativeAuthor권태균-
dc.identifier.doi10.1111/j.1442-2042.2010.02630.x-
dc.citation.journaltitleINTERNATIONAL JOURNAL OF UROLOGY-
dc.description.citedreferenceLeibovich BC, 2010, J UROLOGY, V183, P1309, DOI 10.1016/j.juro.2009.12.035-
dc.description.citedreferenceWaldert M, 2010, EUR UROL, V57, P661, DOI 10.1016/j.eururo.2009.05.009-
dc.description.citedreferenceTeloken PE, 2009, J UROLOGY, V182, P2132, DOI 10.1016/j.juro.2009.07.019-
dc.description.citedreferenceStec R, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-134-
dc.description.citedreferenceJemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006-
dc.description.citedreferenceCapitanio U, 2009, BJU INT, V103, P1496, DOI 10.1111/j.1464-410X.2008.08259.x-
dc.description.citedreferenceEichelberg C, 2009, EUR UROL, V55, P851, DOI 10.1016/j.eururo.2009.01.003-
dc.description.citedreferenceAmin MB, 2008, AM J SURG PATHOL, V32, P1822-
dc.description.citedreferenceKlatte T, 2008, UROL ONCOL-SEMIN ORI, V26, P604, DOI 10.1016/j.urolonc.2007.07.015-
dc.description.citedreferenceTickoo SK, 2008, UROL CLIN N AM, V35, P551, DOI 10.1016/j.ucl.2008.07.001-
dc.description.citedreferenceRaj GV, 2008, J UROLOGY, V179, P2146, DOI 10.1016/j.juro.2008.01.101-
dc.description.citedreferenceKarakiewicz PI, 2007, J CLIN ONCOL, V25, P1316, DOI 10.1200/JCO.2006.06.1218-
dc.description.citedreferencePignot G, 2007, UROLOGY, V69, P230, DOI 10.1016/j.urology.2006.09.052-
dc.description.citedreferenceDelahunt B, 2007, PATHOLOGY, V39, P459, DOI 10.1080/00313020701570061-
dc.description.citedreferenceCAMPBELL SC, 2007, CAMPBELLWALSH UROLOG, P2762-
dc.description.citedreferenceShuch BM, 2006, SEMIN ONCOL, V33, P563, DOI 10.1053/j.seminoncol.2006.06.006-
dc.description.citedreferenceCohen HT, 2005, NEW ENGL J MED, V353, P2477-
dc.description.citedreferenceCindolo L, 2005, CANCER, V104, P1362, DOI 10.1002/cncr.21331-
dc.description.citedreferenceSchuetz AN, 2005, J MOL DIAGN, V7, P206-
dc.description.citedreferencePatard JJ, 2005, J CLIN ONCOL, V23, P2763, DOI 10.1200/JCO.2005.07.055-
dc.description.citedreferenceLAM JS, 2005, CURR UROL REP, V6, P7-
dc.description.citedreferenceKim H, 2004, HUM PATHOL, V35, P1556, DOI 10.1016/j.humpath.2004.06.011-
dc.description.citedreferencePatard JJ, 2004, J CLIN ONCOL, V22, P3316, DOI 10.1200/JCO.2004.09.104-
dc.description.citedreferenceFurge KA, 2004, CANCER RES, V64, P4117-
dc.description.citedreferenceBeck SDW, 2004, ANN SURG ONCOL, V11, P71, DOI 10.1245/ASO.2004.06.016-
dc.description.citedreferenceEBLE JN, 2004, WHO CLASSIFICATION T, P12-
dc.description.citedreferenceGREENE FL, 2002, AJCC CANC STAGING MA, P323-
dc.description.citedreferenceKattan MW, 2001, J UROLOGY, V166, P63-
dc.description.citedreferenceKovacs G, 1997, J PATHOL, V183, P131-
dc.description.citedreferenceDelahunt B, 1997, MODERN PATHOL, V10, P537-
dc.description.citedreferenceFUHRMAN SA, 1982, AM J SURG PATHOL, V6, P655-
dc.description.tc0-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share